3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution

MT Newswires Live10-24

3SBio's (HKG:1530) subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China, a Thursday Hong Kong bourse filing said.

Shenyang Sunshine will make an upfront payment to RMX Biopharma, a subsidiary of Shanghai Haihe Biopharma Research and Development, as well as milestone payments for sales and research and development.

The ongoing research, development and any related clinical and registration works will still be handled by RMX Biopharma.

The biopharmaceutical company's shares were down over 1% on Thursday's close.

Price (HKD): $6.20, Change: $-0.090, Percent Change: -1.43%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2477214689?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-24 19:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477214689","market":"sh","top_or_hot":-1,"title":"3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution","media":"MT Newswires Live","content":"<html><body><p> 3SBio's (HKG:1530) subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China, a Thursday Hong Kong bourse filing said.</p><p>Shenyang Sunshine will make an upfront payment to RMX Biopharma, a subsidiary of Shanghai Haihe Biopharma Research and Development, as well as milestone payments for sales and research and development.</p><p>The ongoing research, development and any related clinical and registration works will still be handled by RMX Biopharma.</p><p>The biopharmaceutical company's shares were down over 1% on Thursday's close.</p><p>Price (HKD): $6.20, Change: $-0.090, Percent Change: -1.43%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3SBio Arm to Obtain Commercialization Rights for RMX Biopharma's Paclitaxel Oral Solution\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 19:26 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>3SBio's (HKG:1530) subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01530","symbol_name":"三生制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2477214689","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477214689","pubTimestamp":1729769201,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"3SBio's  subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China, a Thursday Hong Kong bourse filing said.Shenyang Sunshine will make an upfront payment to RMX Biopharma, a subsidiary of Shanghai Haihe Biopharma Research and Development, as well as milestone payments for sales and research and development.The ongoing research, development and any related clinical and registration works will still be handled by RMX Biopharma.The biopharmaceutical company's shares were down over 1% on Thursday's close.Price : $6.20, Change: $-0.090, Percent Change: -1.43%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"688981":"中芯国际","01530":"三生制药","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","BK4585":"ETF&股票定投概念","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK1583":"高瓴概念","BK1161":"生物科技","BK1593":"医美概念股","BK4588":"碎股","BK4141":"半导体产品","BK4023":"应用软件","BK4526":"热门中概股","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC","HKD":"尚乘数科"},"translate_title":"三生制药Arm将获得RMX Biopharma紫杉醇口服溶液商业化权利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"688981":0.7,"HKD":1,"01530":0.9},"content_text":"3SBio's (HKG:1530) subsidiary Shenyang Sunshine Pharmaceutical will obtain the exclusive commercialization rights of Shanghai RMX Biopharma's product of paclitaxel oral solution in Hong Kong and China, a Thursday Hong Kong bourse filing said.Shenyang Sunshine will make an upfront payment to RMX Biopharma, a subsidiary of Shanghai Haihe Biopharma Research and Development, as well as milestone payments for sales and research and development.The ongoing research, development and any related clinical and registration works will still be handled by RMX Biopharma.The biopharmaceutical company's shares were down over 1% on Thursday's close.Price (HKD): $6.20, Change: $-0.090, Percent Change: -1.43%","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Company Corporation","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.2","shortVersion":"4.29.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2477214689"}